A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn’s DiseaseStefan Schreiber, Edward V. Loftus, Keith Friedenberg et al.|Journal of Crohn s and Colitis|2018Cited by 51